Elise De Vos
YOU?
Author Swipe
View article: Improving the efficiency of drug resistant tuberculosis treatment trials: a time-to-event alternative marker for bacteriological response and adaptive minimization for randomization
Improving the efficiency of drug resistant tuberculosis treatment trials: a time-to-event alternative marker for bacteriological response and adaptive minimization for randomization Open
Background Establishing the efficacy of new treatments for rifampicin-resistant tuberculosis (RR-TB) is challenging due to the long-term clinical endpoints of two-year relapse-free survival. This study aimed to evaluate the effect of an al…
View article: Epidemiological characteristics of mpox virus Clade Ib in the Democratic Republic of the Congo: the impact of transmission mode
Epidemiological characteristics of mpox virus Clade Ib in the Democratic Republic of the Congo: the impact of transmission mode Open
Monkeypox virus (MPXV) Clade Ib, a new MPXV subclade associated with sustained human-to-human transmission, emerged in eastern DRC in late 2023. Early spread mainly occurred among the adult population, primarily through sexual contact. We …
View article: No Distinct Cytokine, Chemokine, and Growth Factor Blood Profile Associated With Monkeypox Virus Clade IIb Infected Patients
No Distinct Cytokine, Chemokine, and Growth Factor Blood Profile Associated With Monkeypox Virus Clade IIb Infected Patients Open
Previous studies indicated Clade I monkeypox virus infection to be associated with marked elevation of proinflammatory cytokines. This remains unexplored for Clade II‐associated disease, which has different clinical manifestations and prog…
View article: Outbreak of cholera in the Southwest region of Cameroon, 2021-22: an epidemiological investigation
Outbreak of cholera in the Southwest region of Cameroon, 2021-22: an epidemiological investigation Open
View article: Potential determinants of the decline in mpox cases in Belgium: A behavioral, epidemiological and seroprevalence study
Potential determinants of the decline in mpox cases in Belgium: A behavioral, epidemiological and seroprevalence study Open
View article: Mpox in the Democratic Republic of Congo: Analysis of National Epidemiological and Laboratory Surveillance Data, 2010 - 2023
Mpox in the Democratic Republic of Congo: Analysis of National Epidemiological and Laboratory Surveillance Data, 2010 - 2023 Open
View article: Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality
Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality Open
Studies assessing patient-centred outcomes of novel rifampicin resistant tuberculosis (RR-TB) diagnostics are rare and mostly apply conventional methods which may not adequately address biases. Even though the Xpert MTB/RIF molecular assay…
View article: Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality
Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality Open
Studies assessing patient-centred outcomes of novel rifampicin resistant tuberculosis (RR-TB) diagnostics are rare and mostly apply conventional methods which may not adequately address biases. Even though the Xpert MTB/RIF molecular assay…
View article: Detection of mpox virus in ambient air in a sexual health clinic
Detection of mpox virus in ambient air in a sexual health clinic Open
View article: Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial Open
View article: Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial Open
Background : Rifampicin-resistant tuberculosis (RR-TB) remains an important global health problem. Ideally, the complete drug-resistance profile guides individualized treatment for all RR-TB patients, but this is only practised in high-inc…
View article: Variants in Bedaquiline-Candidate-Resistance Genes: Prevalence in Bedaquiline-Naive Patients, Effect on MIC, and Association with Mycobacterium tuberculosis Lineage
Variants in Bedaquiline-Candidate-Resistance Genes: Prevalence in Bedaquiline-Naive Patients, Effect on MIC, and Association with Mycobacterium tuberculosis Lineage Open
Studies have shown that variants in bedaquiline-resistance genes can occur in isolates from bedaquiline-naive patients. We assessed the prevalence of variants in all bedaquiline-candidate-resistance genes in bedaquiline-naive patients, inv…
View article: Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa
Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa Open
Extensively drug-resistant tuberculosis (XDR-TB), defined as resistance to at least isoniazid (INH), rifampicin (RIF), a fluoroquinolone (FQ) and a second-line injectable drug (SLID), is difficult to treat and poses a major threat to TB co…
View article: Detection of minor variants in <i>Mycobacterium tuberculosis</i> whole genome sequencing data
Detection of minor variants in <i>Mycobacterium tuberculosis</i> whole genome sequencing data Open
The study of genetic minority variants is fundamental to the understanding of complex processes such as evolution, fitness, transmission, virulence, heteroresistance and drug tolerance in Mycobacterium tuberculosis (Mtb). We evaluated the …
View article: Role of empiric treatment in hospitalized patients with Xpert MTB/RIF-negative presumptive pulmonary tuberculosis: A prospective cohort study
Role of empiric treatment in hospitalized patients with Xpert MTB/RIF-negative presumptive pulmonary tuberculosis: A prospective cohort study Open
Clinical algorithm identifies the majority of confirmed tuberculosis cases among Xpert-negative inpatients. Empiric treatment did not impact survival and resulted in substantial overtreatment. The more sensitive Xpert Ultra assay should be…
View article: Discordances between molecular assays for rifampicin resistance in <i>Mycobacterium tuberculosis</i>: frequency, mechanisms and clinical impact
Discordances between molecular assays for rifampicin resistance in <i>Mycobacterium tuberculosis</i>: frequency, mechanisms and clinical impact Open
Background Molecular assays are endorsed for detection and confirmation of rifampicin-resistant TB. The frequency, causal mechanisms and impact of discordant results between molecular tests are not well understood. Methods The prevalence o…
View article: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis
The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis Open
Identification of the exact rpoB polymorphism leading to the diagnosis of RR-TB has the potential to allow inclusion of rifabutin in the treatment regimen of a substantial proportion of RR-TB patients. A randomized controlled trial evaluat…